XLO S-3/A SEC Filing Analysis

Latest settled — T+5d

XLO ▼ -4.40% at T+5d

NEUTRAL call ✗ call lost -4.40% · α vs SPY -4.35% · entry $8.52 → $8.15

Next anchor: T+20d in 12d

Currently $8.31 · -2.46% from $8.52 entry

Entry anchored
May 27, 03:57 PM ET
via Databento tick

T+1d

-0.70%

call -0.70% · α -0.95%

$8.46

settled 16d ago

T+5d

-4.40%

call -4.40% · α -4.35%

$8.15

settled 10d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in securities (common, preferred, debt, units, warrants) including a $14.5M ATM facility with Leerink Partners. The company has already sold $4.6M under the prior S-3 and has a $72.5M net tangible book value as of March 31, 2026. The filing is a routine shelf update to reflect prior sales and updated public float calculations, with no new capital being raised at this time.

Key Financial Metrics

Offering Size

$250.0M

Actionable Insight

This is a routine shelf update with no immediate capital raise. Monitor for future ATM sales or prospectus supplements that would signal actual dilution. The company's cash position and burn rate from the 10-Q will determine if and when they tap this facility.

Key Facts

Shelf registration for up to $250M in securities, including a $14.5M ATM facility with Leerink Partners
$4.6M already sold under the prior S-3 (File No. 333-285703) prior to this amendment
Public float calculated at ~$57.6M as of May 26, 2026, limiting primary offerings to 1/3 of float per I.B.6
Net tangible book value of $72.5M ($12.55/share) as of March 31, 2026
Pro forma net tangible book value of $72.6M ($3.80/share) including 13.3M prefunded warrants
Stock price at filing: $8.35/share (May 26, 2026); market cap ~$50M

Financial Impact

No new capital raised; shelf capacity of $250M with $14.5M ATM component; $4.6M already utilized under prior S-3

dilutionequity

Risk Factors

Potential future dilution from ATM sales or other shelf takedowns
I.B.6 limitation restricts primary offerings to ~$19.2M (1/3 of $57.6M public float) in any 12-month period
Pre-funded warrants (13.3M shares at $0.0014) represent massive potential dilution if exercised

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

80% bullish (5 analysts)

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

Document	Accession Number
S-3/A Filing (Primary)	0001193125-26-242204
Document: xlo-ex4_4.htm	0001193125-26-242204

9 reports for XLO

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +8.40%Mar 23, 2026

Filters

Reports for XLO — sortable, filterable
	Type				Now
Jun 1, 2026 12d ago	EFFECT BEARISH ★ 5/10	$8.25 $7.70	▲ +6.67%	▲ +3.92%	$8.31 (−0.73%)
May 27, 2026 16d ago	S-3/A NEUTRAL ★ 4/10	$8.52 $8.15	▼ −4.40%	▼ −4.35%	$8.31 (−2.46%)
May 12, 2026 4w ago	8-K NEUTRAL ★ 4/10	$7.73 $8.15	▲ +5.43%	▲ +5.36%	$8.31 (+7.50%)
May 12, 2026 4w ago	Press Release BULLISH ★ 7/10	$7.73 $8.15	▲ +5.43%	▲ +5.36%	$8.31 (+7.50%)
Apr 17, 2026 8w ago	Press Release MIXED ★ 5/10	$8.45 $8.18	▼ −3.20%	▼ −4.11%	$8.31 (−1.66%)
Apr 16, 2026 8w ago	3 NEUTRAL ★ 2/10	$8.57 $8.31	▼ −3.03%	▼ −3.59%	$8.31 (−3.03%)
Apr 16, 2026 8w ago	8-K NEUTRAL ★ 3/10	$8.35 $8.47	▲ +1.44%	▲ +0.45%	$8.31 (−0.48%)
Mar 23, 2026 11w ago	Press Release BULLISH ★ 8/10	$7.86 $8.24	▲ +4.77%	▲ +8.34%	$8.31 (+5.73%)
Mar 17, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$7.60 $8.53	▲ +12.24%	▲ +12.95%	$8.31 (+9.34%)

US Market Status

Market Closed — Opens Mon (50h 43m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access